CSCO 2024 | Dr. Zefei Jiang: Twenty Years of Mutual Achievement, From China to the World; A Preview of the Exciting 2024 CSCO Conference

CSCO 2024 | Dr. Zefei Jiang: Twenty Years of Mutual Achievement, From China to the World; A Preview of the Exciting 2024 CSCO Conference

From September 25 to 29, 2024, the 27th Annual National Clinical Oncology Conference and 2024 CSCO Academic Conference, organized by the Chinese Society of Clinical Oncology (CSCO) and the Beijing CISCO Clinical Oncology Research Foundation, will be held in Xiamen. With the theme "Patient-Centered, Sharing the Future," the conference will showcase important research advancements and trends in the field, both domestically and internationally. For over two decades, CSCO has been at the forefront of clinical oncology development in China, and numerous experts and scholars have played integral roles in its evolution, growing along with CSCO. To honor this journey, Oncology Frontier has established a special column, "Growing Together with CSCO," to reflect on these experiences with Chinese scholars. In this inaugural issue, we are pleased to interview Dr. Zefei Jiang, Vice President and Secretary General of CSCO and a professor at the The Fifth Medical Center of Chinese PLA General Hospital, who shares his personal journey of growth with CSCO and highlights the exciting features of the 2024 CSCO Conference.
ASTRO 2024 Highlights: Dr. Kristin Higgins on Optimal Sequence for SCLC Therapies

ASTRO 2024 Highlights: Dr. Kristin Higgins on Optimal Sequence for SCLC Therapies

At the 2024 Annual Meeting of the American Society for Radiation Oncology (ASTRO), the second interim analysis of the Phase III NRG-LU005 trial revealed the importance of timing when combining immunotherapy with chemoradiotherapy for limited-stage small cell lung cancer (SCLC). The findings showed no significant survival benefits for patients who received atezolizumab concurrently with chemoradiotherapy (cCRT) compared to those who received cCRT alone.
CSCO 2024 | Dr. Ruihua Xu: Patient-Centered Approach to Innovating the Future of Cancer Treatment

CSCO 2024 | Dr. Ruihua Xu: Patient-Centered Approach to Innovating the Future of Cancer Treatment

From September 25 to 29, 2024, the 27th National Clinical Oncology Conference and 2024 CSCO Annual Meeting, organized by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, were held in Xiamen. The theme of this year’s conference was “Patient-Centered, Sharing the Future,” bringing together key research advancements and developments in the field from both China and abroad. During the conference, Oncology Frontier had the pleasure of interviewing the conference chair, Dr. Ruihua Xu from Sun Yat-sen University Cancer Center. Professor Xu emphasized the importance of a patient-centered approach to cancer treatment, showcased the latest advances in immunotherapy, and highlighted future research directions and current challenges.
CUA 2024 Presents: Advancing Kidney-Sparing Strategies for UTUC

CUA 2024 Presents: Advancing Kidney-Sparing Strategies for UTUC

Radical nephroureterectomy (RNU) remains the gold standard treatment for upper tract urothelial carcinoma (UTUC). However, some patients with a solitary kidney or insufficient renal reserve may require alternative approaches to preserve kidney function. In recent years, advancements in systemic drug therapy and various endoscopic focal treatment techniques have provided kidney-sparing options for such patients. Nonetheless, large-scale case reports or prospective studies remain scarce. At the 31st Urology Academic Conference (CUA 2024), organized by the Chinese Medical Association and the Chinese Urological Association, Dr. Qiang Wei and  Yige Bao from West China Hospital, Sichuan University, presented their report on multimodal kidney-sparing treatment in 62 patients with high-risk localized UTUC.
ESMO 2024 Pioneers: Dr. Filippo Pietrantonio on the Cutting Edge of Upper GI Cancer Research

ESMO 2024 Pioneers: Dr. Filippo Pietrantonio on the Cutting Edge of Upper GI Cancer Research

As one of the world's largest and most academically prestigious clinical oncology conferences, the 2024 European Society for Medical Oncology (ESMO) conference, held from September 13 to 17 in Barcelona, drew global attention. The conference revealed several important clinical study results in upper gastrointestinal tumors. Dr. Filippo Pietrantonio, an oncologist from the National Cancer Institute in Milan, Italy, shared his insights in an exclusive interview with Oncology Frontier.